Halozyme Therapeutics Inc. reported robust financial results for the second quarter of 2025, with total revenue increasing by 41% year-over-year to $326 million and royalty revenue surging by 65% year-over-year to $206 million. The company's net income rose by 77% year-over-year to reach $165 million. Additionally, the GAAP Diluted EPS saw an 85% increase year-over-year to $1.33, while Non-GAAP Diluted EPS increased by 69% year-over-year to $1.54. The company also raised its full-year 2025 financial guidance, projecting total revenue to be in the range of $1,275 to $1,355 million, reflecting a year-over-year growth of 26% to 33%. Adjusted EBITDA guidance was also increased to a range of $865 to $915 million, indicating a growth of 37% to 45% year-over-year. Non-GAAP Diluted EPS is now anticipated to be between $6.00 and $6.40, representing a growth of 42% to 51% year-over-year. Significant business updates include the authorization of a third $250 million share repurchase tranche under a $750 million authorized plan. The company achieved notable regulatory milestones with approvals in Europe and the US, including the RYBREVANT SC and VYVGART Hytrulo products. Halozyme continues to expand its ENHANZE drug delivery technology, enhancing its growth trajectory and patient access globally.